A Case Report and Literature Review of A Child with Refractory Anti-N-methyl-D-aspartate Receptor Encephalitis Treated with Tocilizumab
10.13748/j.cnki.issn1007-7693.20232480
- VernacularTitle:托珠单抗治疗1例儿童难治性抗N-甲基-D-天冬氨酸受体脑炎的病例报告及文献复习
- Author:
Weiqin ZHANG
1
,
2
;
Huawei ZHAO
1
,
3
;
Zhenzhen WANG
1
,
2
;
Feng GAO
1
,
2
;
Zhefeng YUAN
1
,
2
Author Information
1. Children&rsquo
2. s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Department of Neurology
3. s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Department of Pharmacy, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
tocilizumab；children ； refractory；anti-NMDAR encephalitis
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(6):834-838
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To explore the safety and efficacy of tocilizumab in the treatment of refractory anti-N-methyl-D-aspartate receptor encephalitis in children, and to provide reference for the treatment of this disease.
METHODS
The clinical manifestations, diagnosis and treatment, safety and efficacy of tocilizumab in a case of refractory anti-NMDAR encephalitis in Children’s Hospital, Zhejiang University School of Medicine were analyzed retrospectively, and the relevant literature was reviewed.
RESULTS
The clinical symptoms of the patient were not improved after 2 doses of methylprednisolone, immunoglobulin and 6 doses of rituximab. After 6 doses of tocilizumab, the modified Rankin scale(mRS) score was improved without adverse reactions.
CONCLUSION
Tocilizumab, as a escalation second-line immunotherapy, is effective and well tolerated in the treatment of refractory anti-NMDAR encephalitis. It is one of the potential therapeutic means.
